Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia

BMC Health Services Research

Lucia Kris Dinarti¹  Oktavia Lilyasari²  Septiara Putri³  Yot Teerawattananon⁴  Thanaporn Bussabawalai⁴  Yusuf Subekti⁵  Nur Atika⁵  Anggita Bunga Anggraini⁶  Cicih Opitasari⁶ 

[1] Department of Cardiology, Gadjah Mada University;Department of Cardiology, Medical School, University of Indonesia - Harapan Kita National Hospital;Faculty of Public Health, University of Indonesia;Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health;Indonesian Health Technology Assessment Committee;National Institute of Health Research, Ministry of Health;

关键词: Economic evaluation;    Sildenafil;    Beraprost;    Pulmonary arterial hypertension;    PAH;    Indonesia;   

DOI  :  10.1186/s12913-019-4422-5

来源: DOAJ

【 摘 要 】

Abstract Background This study aims to assess the cost-effectiveness and budget impact of adopting sildenafil to the benefits package for the indication of pulmonary arterial hypertension (PAH), compared to beraprost. Methods Based on a societal perspective, a model-based economic evaluation was performed using local and international data to quantify the potential costs and health-related outcomes in terms of life years (LYs) and quality-adjusted life years (QALYs). Results The economic model calculated the incremental cost-effectiveness ratio (ICER) per QALY gained for using sildenafil as first-line therapy compared to beraprost for the patient in functional class (FC) II and III, i.e. USD 3098 and USD 2827, respectively. The results indicated that in spite of sildenafil being more expensive than beraprost, generic sildenafil could potentially be a good value for money since ICER per QALY is below one times gross domestic product (GDP) per capita in Indonesia. Furthermore, budget impact analysis estimated that the incremental budget needed within 5 years for including sildenafil compared to beraprost for PAH patients starting in FC II and FC III was USD 436,775 and USD 3.6 million, respectively. Conclusions Compared to beraprost, sildenafil would be preferable for the treatment of PAH patients in FC II and FC III in Indonesia. The additional budget for adopting sildenafil compared to beraprost as the treatment of PAH in the benefits package was estimated at around USD 4.0 million.

【 授权许可】

Unknown